{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:00:38Z","timestamp":1775473238679,"version":"3.50.1"},"reference-count":34,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>This study aimed to evaluate the efficacy and safety of combination therapy with bevacizumab (Bev), irinotecan (CPT-11), and temozolomide (TMZ) in children with central nervous system (CNS) embryonal tumor relapse.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>The authors retrospectively examined 13 consecutive pediatric patients with relapsed or refractory CNS embryonal tumors who received combination therapy comprising Bev, CPT-11, and TMZ. Specifically, 9 patients had medulloblastoma, 3 had atypical teratoid\/rhabdoid tumor (AT\/RT), and 1 had CNS embryonal tumor with rhabdoid features. Of the 9 medulloblastoma cases, 2 were categorized in the Sonic hedgehog subgroup and 6 in molecular subgroup 3 for medulloblastoma.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>The complete and partial objective response rates were 66.6% in patients with medulloblastoma and 75.0% in patients with AT\/RT or CNS embryonal tumors with rhabdoid features. Furthermore, the 12- and 24-month progression-free survival rates were 69.2% and 51.9% for all patients with recurrent or refractory CNS embryonal tumors, respectively. In contrast, the 12- and 24-month overall survival rates were 67.1% and 58.7%, respectively, for all patients with relapsed or refractory CNS embryonal tumors. The authors observed grade 3 neutropenia, thrombocytopenia, proteinuria, hypertension, diarrhea, and constipation in 23.1%, 7.7%, 23.1%, 7.7%, 7.7%, and 7.7% of patients, respectively. Furthermore, grade 4 neutropenia was observed in 7.1% of patients. Nonhematological adverse effects, such as nausea and constipation, were mild and controlled with standard antiemetics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>This study demonstrated favorable survival outcomes in patients with relapsed or refractory pediatric CNS embryonal tumors and thus helped to investigate the efficacy of combination therapy comprising Bev, CPT-11, and TMZ. Moreover, combination chemotherapy had high objective response rates, and all adverse events were tolerable. To date, data supporting the efficacy and safety of this regimen in the relapsed or refractory AT\/RT population are limited. These findings suggest the potential efficacy and safety of combination chemotherapy in patients with relapsed or refractory pediatric CNS embryonal tumors.<\/jats:p>\n<\/jats:sec>","DOI":"10.3171\/2023.1.peds22345","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T06:40:46Z","timestamp":1678516846000},"page":"624-632","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of bevacizumab, irinotecan, and temozolomide combination for relapsed or refractory pediatric central nervous system embryonal tumor: a single-institution study"],"prefix":"10.3171","volume":"31","author":[{"given":"Yoshiki","family":"Shiba","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Motomura","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Pediatrics, Nagoya University School of Medicine, Nagoya;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Kurimoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Aichi Children\u2019s Health and Medical Center, Nagoya; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiharu","family":"Ohka","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Ito","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kibe","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"},{"name":"Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Pediatrics, Nagoya University School of Medicine, Nagoya;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Pediatrics, Nagoya University School of Medicine, Nagoya;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"issue":"7","key":"b1","series-title":"Neuro Oncol","first-page":"975","article-title":"Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors","volume":"16","author":"Desandes E","year":"2014","unstructured":"Desandes E, Guissou S, Chastagner P, Lacour B. Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors. Neuro Oncol. 2014;16(7):975\u2013983."},{"issue":"7","key":"b2","series-title":"Curr Probl Pediatr Adolesc Health Care","first-page":"242","article-title":"Pediatric brain tumors: an update","volume":"46","author":"Segal D","year":"2016","unstructured":"Segal D, Karajannis MA. Pediatric brain tumors: an update. Curr Probl Pediatr Adolesc Health Care. 2016;46(7):242\u2013250.27230809"},{"issue":"Suppl 10","key":"b3","series-title":"Neuro Oncol","first-page":"x1","article-title":"Alex\u2019s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom QT","year":"2015","unstructured":"Ostrom QT, de Blank PM, Kruchko C,  Alex\u2019s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011. Neuro Oncol. 2015;16(Suppl 10):x1\u2013x36.25542864"},{"issue":"9","key":"b4","series-title":"Am J Surg Pathol","first-page":"1083","article-title":"Atypical teratoid\/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study","volume":"22","author":"Burger PC","year":"1998","unstructured":"Burger PC, Yu IT, Tihan T,  Atypical teratoid\/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998;22(9):1083\u20131092."},{"issue":"1","key":"b5","series-title":"J Neurosurg","first-page":"56","article-title":"Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood: definition of an entity","volume":"85","author":"Rorke LB","year":"1996","unstructured":"Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85(1):56\u201365.8683283"},{"issue":"5","key":"b6","series-title":"Am J Surg Pathol","first-page":"644","article-title":"Immunohistochemical analysis of hSNF5\/INI1 in pediatric CNS neoplasms","volume":"28","author":"Judkins AR","year":"2004","unstructured":"Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5\/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004;28(5):644\u2013650.15105654"},{"issue":"6","key":"b7","series-title":"Am J Surg Pathol","first-page":"933","article-title":"Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid\/rhabdoid tumor showing retained SMARCB1 (INI1) expression","volume":"35","author":"Hasselblatt M","year":"2011","unstructured":"Hasselblatt M, Gesk S, Oyen F,  Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid\/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 2011;35(6):933\u2013935."},{"issue":"7","key":"b8","series-title":"J Clin Oncol","first-page":"822","article-title":"Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)","volume":"39","author":"Gajjar A","year":"2021","unstructured":"Gajjar A, Robinson GW, Smith KS,  Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol. 2021;39(7):822\u2013835.33405951"},{"issue":"5","key":"b9","series-title":"Pediatr Blood Cancer","first-page":"675","article-title":"Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma","volume":"51","author":"Kadota RP","year":"2008","unstructured":"Kadota RP, Mahoney DH, Doyle J,  Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer. 2008;51(5):675\u2013678."},{"issue":"21","key":"b10","series-title":"Cancer","first-page":"4977","article-title":"Reirradiation for recurrent medulloblastoma","volume":"117","author":"Bakst RL","year":"2011","unstructured":"Bakst RL, Dunkel IJ, Gilheeney S,  Reirradiation for recurrent medulloblastoma. Cancer. 2011;117(21):4977\u20134982.21495027"},{"key":"b11","series-title":"J Oncol","first-page":"247873","article-title":"Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature","volume":"2009","author":"Privitera G","year":"2009","unstructured":"Privitera G, Acquaviva G, Ettorre GC, Spatola C. Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature. J Oncol. 2009;2009:247873.20111585"},{"issue":"11","key":"b12","series-title":"Oncologist","first-page":"1131","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen MH","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131\u20131138.19897538"},{"issue":"29","key":"b13","series-title":"J Clin Oncol","first-page":"4622","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"25","author":"Bomgaars LR","year":"2007","unstructured":"Bomgaars LR, Bernstein M, Krailo M,  Phase II trial of irinotecan in children with refractory solid tumors: a Children\u2019s Oncology Group Study. J Clin Oncol. 2007;25(29):4622\u20134627."},{"issue":"5","key":"b14","series-title":"Childs Nerv Syst","first-page":"535","article-title":"Efficacy of temozolomide for recurrent embryonal brain tumors in children","volume":"25","author":"Wang CH","year":"2009","unstructured":"Wang CH, Hsu TR, Wong TT, Chang KP. Efficacy of temozolomide for recurrent embryonal brain tumors in children. Childs Nerv Syst. 2009;25(5):535\u2013541.19107490"},{"issue":"7","key":"b15","series-title":"Cancer","first-page":"1542","article-title":"Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children\u2019s Oncology Group","volume":"110","author":"Nicholson HS","year":"2007","unstructured":"Nicholson HS, Kretschmar CS, Krailo M,  Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children\u2019s Oncology Group. Cancer. 2007;110(7):1542\u20131550.17705175"},{"issue":"8","key":"b16","series-title":"Pediatr Blood Cancer","first-page":"e29031","article-title":"Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial","volume":"68","author":"Levy AS","year":"2021","unstructured":"Levy AS, Krailo M, Chi S,  Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. 2021;68(8):e29031.33844469"},{"issue":"6","key":"b17","series-title":"Acta Neuropathol","first-page":"803","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G,  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803\u2013820.27157931"},{"issue":"12","key":"b18","series-title":"Bioinformatics","first-page":"1572","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson MD","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20131573.20427518"},{"issue":"4","key":"b19","series-title":"Cancer Chemother Pharmacol","first-page":"727","article-title":"Evaluation of the exposure equivalence of oral versus intravenous temozolomide","volume":"65","author":"Diez BD","year":"2010","unstructured":"Diez BD, Statkevich P, Zhu Y,  Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemother Pharmacol. 2010;65(4):727\u2013734.19641919"},{"issue":"28","key":"b20","series-title":"J Clin Oncol","first-page":"4733","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman HS","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY,  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733\u20134740.19720927"},{"issue":"2","key":"b21","series-title":"Hematol Oncol Clin North Am","first-page":"333","article-title":"Topoisomerase I inhibitors. An overview of the camptothecin analogs","volume":"8","author":"Burris HA III","year":"1994","unstructured":"Burris HA III, Fields SM. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Hematol Oncol Clin North Am. 1994;8(2):333\u2013355.8040144"},{"issue":"4","key":"b22","series-title":"J Natl Cancer Inst","first-page":"271","article-title":"The current status of camptothecin analogues as antitumor agents","volume":"85","author":"Slichenmyer WJ","year":"1993","unstructured":"Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85(4):271\u2013291.8381186"},{"key":"b23","series-title":"National Cancer Institute.","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"issue":"3","key":"b24","series-title":"J Pediatr Hematol Oncol","first-page":"e159","article-title":"Survival following tumor recurrence in children with medulloblastoma","volume":"40","author":"Johnston DL","year":"2018","unstructured":"Johnston DL, Keene D, Strother D,  Survival following tumor recurrence in children with medulloblastoma. J Pediatr Hematol Oncol. 2018;40(3):e159\u2013e163.29432312"},{"issue":"5","key":"b25","series-title":"Neuro Oncol","first-page":"745","article-title":"Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma","volume":"10","author":"Gururangan S","year":"2008","unstructured":"Gururangan S, Krauser J, Watral MA,  Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008;10(5):745\u2013751."},{"issue":"5","key":"b26","series-title":"Neuro Oncol","first-page":"748","article-title":"Temozolomide is an active agent in children with recurrent medulloblastoma\/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial","volume":"16","author":"Cefalo G","year":"2014","unstructured":"Cefalo G, Massimino M, Ruggiero A,  Temozolomide is an active agent in children with recurrent medulloblastoma\/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro Oncol. 2014;16(5):748\u2013753.24482446"},{"issue":"9","key":"b27","series-title":"Neuro Oncol","first-page":"1236","article-title":"Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study","volume":"15","author":"Grill J","year":"2013","unstructured":"Grill J, Geoerger B, Gesner L,  Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro Oncol. 2013;15(9):1236\u20131243.23857707"},{"issue":"4","key":"b28","series-title":"Childs Nerv Syst","first-page":"589","article-title":"Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience","volume":"29","author":"Aguilera D","year":"2013","unstructured":"Aguilera D, Mazewski C, Fangusaro J,  Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013;29(4):589\u2013596.23296323"},{"issue":"15","key":"b29","series-title":"Cancer","first-page":"3812","article-title":"Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study","volume":"118","author":"Dufour C","year":"2012","unstructured":"Dufour C, Beaugrand A, Le Deley MC,  Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study. Cancer. 2012;118(15):3812\u20133821.22180295"},{"issue":"6","key":"b30","series-title":"Pediatr Blood Cancer","first-page":"978","article-title":"Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT\/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database","volume":"57","author":"von Hoff K","year":"2011","unstructured":"von Hoff K, Hinkes B, Dannenmann-Stern E,  Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT\/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer. 2011;57(6):978\u2013985."},{"issue":"9","key":"b31","series-title":"J Pediatr Hematol Oncol","first-page":"651","article-title":"Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies","volume":"31","author":"Athale UH","year":"2009","unstructured":"Athale UH, Duckworth J, Odame I, Barr R. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol. 2009;31(9):651\u2013663.19707161"},{"issue":"7","key":"b32","series-title":"J Clin Oncol","first-page":"1491","article-title":"Atypical teratoid\/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy","volume":"23","author":"Tekautz TM","year":"2005","unstructured":"Tekautz TM, Fuller CE, Blaney S,  Atypical teratoid\/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23(7):1491\u20131499.15735125"},{"issue":"3","key":"b33","series-title":"J Clin Oncol","first-page":"385","article-title":"Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor","volume":"27","author":"Chi SN","year":"2009","unstructured":"Chi SN, Zimmerman MA, Yao X,  Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27(3):385\u2013389.19064966"},{"issue":"1","key":"b34","series-title":"J Neurooncol","first-page":"81","article-title":"Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature","volume":"126","author":"Schrey D","year":"2016","unstructured":"Schrey D, Carceller Lech\u00f3n F, Malietzis G,  Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neurooncol. 2016;126(1):81\u201390.26608522"}],"container-title":["Journal of Neurosurgery: Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-pediatr\/31\/6\/article-p624.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-pediatr\/31\/6\/article-p624.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-pediatr\/31\/6\/article-p624.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T13:04:28Z","timestamp":1733490268000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-pediatr\/31\/6\/article-p624.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":34,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2023.1.peds22345","relation":{},"ISSN":["1933-0707","1933-0715"],"issn-type":[{"value":"1933-0707","type":"print"},{"value":"1933-0715","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}